Bill > S07668

This bill introduces new regulations for the sale of xylazine, a pharmaceutical drug used for animal sedation and pain relief, by establishing specific restrictions on its sale. The bill defines xylazine and applies to sales of fifty grams or more, prohibiting businesses from selling such quantities to individuals under 21 years old or without proof of institutional, veterinary, or scientific intended use. Businesses selling xylazine must maintain detailed sales records, including proof of age and intended use. Violations of these provisions will result in civil penalties, with first-time offenders facing fines up to $3,000 and subsequent violations incurring $6,500 in penalties. These fines will be collected by the New York State Attorney General and deposited into a state drug treatment and public education fund. The law aims to control the potential misuse of xylazine, which is primarily a veterinary medication, by implementing age restrictions and requiring documentation for larger quantity sales. The bill will go into effect 90 days after becoming law.

Business and Industry

https://www.nysenate.gov/legislation/bills/2025/S7668